The controversy concerning the justification for prostatic cancer scre
ening is now about ten years old. It is the consequence of several con
vergent phenomena: the routine use of new diagnostic tools such as pro
state specific antigen, ageing of Western populations, increased life
expectancy and finally public health economic aspects. Is screening ju
stified before the age of 50 years? The answer is no, except in high-r
isk families with several cases of prostatic cancer, in which screenin
g should be started at the age of 40 years. Is screening justified aft
er the age of 70 years? The answer is no, except in men between 70 and
75 years whose general state and physiological age suggest that they
have a life expectancy exceeding ten years. Is screening justified bet
ween 50 and 70 years? There is no global ''medico-economic'' answer to
this question, as medical truth, i.e. the individual's interests, app
ears to be diametrically opposed to economic truth, i.e. the community
's interests, due to the high cost of screening. How can screening be
envisaged for the future? In families with no particular risk, screeni
ng should be clinical, but will probably start earlier and will contin
ue later, because of the improvement of diagnostic tools and prolongat
ion of life expectancy. In highrisk families, the development of genet
ic tests will be able to determine whether or not a man has inherited
predisposition genes. If he has inherited these genes, he will then be
submitted to particularly early, meticulous and repeated screening.